Effect of highly active antiretroviral therapy on CD4 count and weight in AIDS patients seen at the uith, Ilorin

Nigerian Journal of Clinical Practice

Volumn 11, Issue 4, 2008, Pages 312-315

  Olawumi, H O ^a   Olatunji, P O ^a   Salami, A K ^a   Odeigah, L ^a   Iseniyi, J O ^a  

^a UNIVERSITY OF ILORIN   (Nigeria)

Author keywords

HIV AIDS antiretroviral therapy CD4 weight

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; LAMIVUDINE; NEVIRAPINE; STAVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADOLESCENT; ADULT; AGED; ARTICLE; BODY WEIGHT; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; DRUG EFFECT; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; MALE; MIDDLE AGED; NIGERIA; TEACHING HOSPITAL; TREATMENT OUTCOME; UNIVERSITY HOSPITAL;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADOLESCENT; ADULT; AGED; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BODY WEIGHT; CD4 LYMPHOCYTE COUNT; FEMALE; HOSPITALS, TEACHING; HOSPITALS, UNIVERSITY; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; NEVIRAPINE; NIGERIA; STAVUDINE; TREATMENT OUTCOME;

EID: 65349086166     PISSN: 11193077     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Shafer RW, VuUton DA. HAART for the treatment of infection with HIV-1. Biomedicine and Pharmacotherapy 1999; 53: 73-86.
2. Palmer C. HIV treatments and highly active antiretroviral therapy. Austr. Prescr. 2003; 26: 59-61.
3. + T Cells predict functional response to immunization in chronic HIV-1 infection. AIDS 2003; 17: 2015-2023.
4. Schooley RT. Starting HAART: is it wise to wait? Ann of Intern Med. 2004; 140: 305-306.
5. Youle M, Jannocy G, Turnbull W, Tilling R, Loveday C et al. Changes in.CD4 lymphocyte counts after interruption of therapy in patients with viral failure on protease inhibitorcontaining regimens. Royal Free Centre for HIV Medicine. AIDS. 2000; 14: 1717-1720
6. Verweel G, Van Russum AM, Hartwig NG, Wolfs TF, Scherpbier HJ, de Groot R. Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1 -infected children is associated with a sustained effect on growth. Paediatrics 2002; 109, E 25.
7. Salami AK, Olatunji PO, Oluboyo PO. Spectrum and prognostic significance of opportunistic diseases in HIV/AIDS patients in llorin, Nigeria. WAJM 2006; 25: 52-56.
8. Nemechek P, Polsky B, Gottlieb MS. Treatment guidelines for HIV associated wasting. Mayo Clin Proc 2000; 75: 386-394
9. Tang AM, Forrester J, Apiegelman D. Weight loss and survival in HIV-positive patients in the era of HAART. J Acquir immune defic. Syndr 2002; 31: 230-236.
10. Zuniga-Roiz K, Hernandez-Daly AC, Torres KJ. HAART based on a PI sparing regimen, reconstitutes muscle mass in HIV-infected individuals with wasting syndrome but not in those with moderate or no weight loss. XIV International AIDS Conference, Barcelona, 2002 Abstract Wepe B5 993.
11. Pernerstofer-Schoen H, Schindler K, Parschalk B. Beneficial effects of PI on body composition and resting energy expenditure: a comparison between HIV-infected and noninfected patients. AIDS 1999; 13: 2389-2396
12. Wanke C, Ostrowsky B, Gerrior J, Hestnes J. Effect of HAART on patients' weight and body mass index. Int. Conf AIDS 1998; 12: 1094.
13. Federal Ministry of Health. Guidelines for the use of Antiretroviral (ARV) Drugs in Nigeria. 2005; page 31-31
14. Salami AK, Olatunji PO, OIuboyo PO, Akanbi II AA, Fawibe EA. Bacterial pneumonia in the AIDS patients. WAJM 2006; 25: 1-5.